2020 Annual Report
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Letter From Our President</td>
<td>02</td>
</tr>
<tr>
<td>A Letter From Our Executive Director</td>
<td>03</td>
</tr>
<tr>
<td>A Report From Our Research Committee Chair</td>
<td>04</td>
</tr>
<tr>
<td>2019-2020 Research Funding</td>
<td>06</td>
</tr>
<tr>
<td>Clinical Trial Updates</td>
<td>09</td>
</tr>
<tr>
<td>International Advocacy Efforts</td>
<td>10</td>
</tr>
<tr>
<td>Programs</td>
<td>12</td>
</tr>
<tr>
<td>Fundraising</td>
<td>14</td>
</tr>
<tr>
<td>Testimonials</td>
<td>15</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>19</td>
</tr>
<tr>
<td>Officers at Large</td>
<td>19</td>
</tr>
<tr>
<td>Directors</td>
<td>20</td>
</tr>
<tr>
<td>Scientific Advisory Boards</td>
<td>21</td>
</tr>
<tr>
<td>Staff</td>
<td>23</td>
</tr>
<tr>
<td>Financial Summary</td>
<td>24</td>
</tr>
<tr>
<td>Donors</td>
<td>25</td>
</tr>
</tbody>
</table>
The families, friends, and communities within the Choroideremia Research Foundation have continued our progress towards treatments to stop the loss of vision due to CHM, and to restore lost vision. Our membership resides in over 30 countries, and we are currently funding research in 5 countries. The CRF reaches out to find fellow CHM patients as we think and communicate on a global basis, and continue to collaborate with medical institutions, clinical trial partners and other inherited retinal disease organizations.

Due to the pandemic, the CRF family missed a great opportunity to gather in Rochester, NY last June, allowing for personal camaraderie, informative presentations, and recognizing 20 years of progress driven by the Foundation. Some of those plans have been moved to our virtual platform with additional programs to add in 2021. With the hopes of a global return to some level of normalcy, our thoughts are to plan for an in-person conference in 2022.

Our staff and volunteers have been working to enhance our communications and open additional avenues into the research and support communities. I would like to thank our board and committee members for their time and input over the past year. It is also imperative to recognize those that support the Foundation financially. The CRF only moves forward with volunteer time and effort, continued financial support, and effective staff members. We are fortunate to have all three.

Good health and best wishes to everyone.
A Letter From Our Executive Director

There has never been a more exciting time for research in choroideremia and related inherited retinal diseases (IRD’s). Tremendous progress is accelerating our understanding of gene therapy, stem cell therapy, and RNA therapy. There is also incredible work underway in the areas of retinal prosthetics, eye transplantation, and wearable navigation devices that would have implications for all those with vision loss, regardless of the cause or diagnosis.

Towards this end, we have reached out internationally to over 75 biotech, pharmaceutical, adaptive technology, and assistive device companies to encourage them to consider adding CHM patients to future clinical trials. We have been offering grant funding and research resources such as data sets, cell lines, and animal models if needed. We can also provide patient perspectives and Science Advisory Board feedback on trial design, eligibility criteria, and endpoints as desired.

For new trials to succeed, we must have enough patients who are willing to participate in these trials. To help accomplish this, we reached out to over 50 researchers, clinicians, and allied nonprofits around the world to uncover CHM patients. We are also trying to find more patients through online marketing efforts, encouraging genetic testing to confirm a CHM diagnosis, and conducting outreach to international IRD patient support organizations, and stimulating multi-disciplinary collaboration across the research spectrum.

Together, we WILL find answers and put an end to vision loss and blindness caused by CHM.
The Research Committee of the Choroideremia Research Foundation continues to play a very active role in discovering a cure, in exploring alternative therapies, and developing relationships with investigators. Over the past year the Research Committee has continued to refine our focus on these three main areas of interest.

The research committee continues to advance the science towards finding a cure for choroideremia. To that end we have been very busy this past year on a variety of fronts. Importantly, we have been collaborating with investigators on the development of mouse, porcine, and stem-cell models of choroideremia. Our belief is that these models will give investigators access to the tissues and anatomy they need to understand the basic pathophysiology of choroideremia. Further, these models will allow the study of possible cures and complementary therapies for choroideremia.

The Research Committee is supporting investigations on the female carriers of the aberrant choroideremia gene. Up until recently this particular subset of patients was largely ignored. As life expectancy has increased, however, it is clear that the female carriers of choroideremia can have even significant visual defects later in life. In the future, it is possible that this cohort will greatly benefit from therapies that have yet to be elucidated. Finally, the research committee, in collaboration with members of our scientific advisory board, has proposed a staging system for patients with choroideremia. The next step will be the validation of the staging system.

This past year the research committee has attempted to elevate the science as it relates to choroideremia. We have introduced
a more stringent grant application process. This new grant application requires the presentation of specific objectives, clearly defined endpoints, and a priori statistical calculations. Further, we have made interim reports mandatory. Finally, for those investigators we fund, we are objectively assessing their academic and clinical productivity as it relates to those funds. We are excited that in 2020 we funded the first annual Randy Wheelock award. It just so happens that the research grant that was selected for the Randy Wheelock award is actually investigating a line of research that Randy Wheelock himself first proposed.

Over the past year the research committee has been attempting to increase the engagement of our scientific, industry, and academic thought leaders. As regards the Science Advisory Board, we are being more proactive about their engagement with the grant review process. We are in the process of providing more structure for the members of the Science Advisory Board, and have decided to limit the term of their service to a renewable period of three years. We have also instituted a series of quarterly meetings with the Science Advisory Board, which are used for brainstorming about the direction that the science of choroideremia is headed. Also, we attempt to identify thought leaders with whom the Choroideremia Research Foundation should be formulating a relationship.

In the past year we have funded 15 projects from 11 unique investigators. To extend the amount of projects we are able to fund, we have partnered with other organizations including: CHM Canada, France Choroideremie, the Million Dollar Bike Ride (associated with the Penn Orphan Disease Center), and Fight for Sight. We have funded investigators in the United States, Canada, Portugal, Germany, England, and France. In the United States we have funded investigators from the Universities of California Los Angeles, Michigan, Pennsylvania, and Wisconsin.

The research projects we have chosen to fund generally involve one of three areas. The first is the cellular mechanisms of disease. We have funded investigations looking into the basic function of the REP1 enzyme. We have also funded studies aimed at understanding the photoreceptor structure and function as they relate to choroideremia. We have also funded projects that examine the downstream effects of a mutated REP1 enzyme, such as the regulation of cell death and organelle dysfunction. The second broad area that we have funded centers on gene therapy. Specifically we have looked at the follow-up after gene therapy, the biomarkers associated with gene therapy, and novel vectors that could make gene therapy more efficacious. Our third major area of research centers around the funding of novel projects. To date these projects have looked at the discordant phenotype and brothers that carried the CHM trait and neuroprotection of individuals with CHM.
Since the inception of the Choroideremia Research Foundation in 2000, the organization has provided approximately $4 million in research grants to find treatment options and a cure for CHM. Recent grants have included:

**$61,079 USD**
**Researcher:** Katrina Stingl, MD, Ophthalmologist, Clinical Scientist  
**Institution:** University Eye Hospital, Tübingen, Germany  
Adaptive Optics Imaging in Follow-Ups of Choroideremia Patients after Gene Therapy co-funded with UPENN ODC MDBR  
*Co-funded with University of Pennsylvania Orphan Disease Center via the Million Dollar Bike Ride*

**€40,000**
**Researcher:** Richard Harbottle, PhD, Group Leader, DNA Vector Group Leader  
**Institution:** German Cancer Research Centre, DKFZ, Heidelberg, Germany  
Autonomously Replicating DNA Nanovectors for Gene and Cell Therapy of Choroideremia
<table>
<thead>
<tr>
<th>Amount</th>
<th>Researcher</th>
<th>Institution</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$61,079 USD</td>
<td>David Williams, PhD, Professor in Residence, Ophthalmology</td>
<td>University of California, Los Angeles, CA</td>
<td>Understanding Mitochondrial Defects in Choroideremia</td>
</tr>
<tr>
<td>$50,000 USD</td>
<td>Kim Edwards, Graduate Student</td>
<td>University of Wisconsin, McPherson Eye Research Institute, Madison, WI</td>
<td>RANDY WHEELOCK RESEARCH AWARD WINNER: Identifying the Function of REP-1 Protein in Retina (RPE/Photoreceptors) and Non-Retina Tissues</td>
</tr>
</tbody>
</table>
| $30,000 USD     | David Gamm, MD, PhD, Director, McPherson Eye Research Institute; Associate Professor, Ophthalmology and Visual Sciences | University of Wisconsin, McPherson Eye Research Institute, Madison, WI | Randy Wheelock Research Award Budget Supplement  

This supplement grant provides for the strategic expansion of the CRF CHM Biobank by tripling the number of current cell lines (IPSCs - induced pluripotent stem cells) which are now crucial building blocks in current and future CHM research. |
| $59,459 CAN     | Abigail Fahim, MD, PhD, Clinical Assistant Professor, Ophthalmology and Visual Sciences | Kellogg Eye Center, University of Michigan, Ann Arbor, MI | Investigating Choroideremia Pathophysiology using iPSC-derived Retinal Pigment Epithelium  

Co-funded with CRF Canada |
| $61,079 CAN     | Stacey Hume, PhD, FCCMG, Associate Professor, Department of Medical Genetics | University of Alberta, Canada | BOREN FAMILY RESEARCH AWARD: Identifying the Cause of a Discordant Phenotype in Two Brothers with the Identical CHM Mutation  

Co-funded with CRF Canada |
$37,848 CAN
Researcher: Yi (Fay) Zhai, MD, PhD, Clinical Research Fellow, Department of Ophthalmology
Institution: University of Alberta, Canada
OSTER FAMILY RESEARCH AWARD: Measuring the En Face Ellipsoid Zone (EZ) Area as a Biomarker of Photoreceptor Structure/Function in Choroideremia
Co-funded with CRF Canada

£60,000
Researcher: Mariya Moosajee, MBBS, BSc (Hons), PhD, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Academic Ophthalmologist
Institution: University College, London, UK
SALOIS FAMILY RESEARCH AWARD: Neuroprotection for Choroideremia
Co-funded with CRF Canada

€45,000
Researcher: Vasiliki Kalatzis, PhD, Human Genetics, HDR Life Sciences
Institution: Institute for Neurosciences of Montpellier, INSERM, France
GLEASON FAMILY RESEARCH AWARD: A Novel Approach to Unravelling the Pathophysiology of CHM using iPSC-derived RPE from Patients
Co-funded with CRF Canada

Click here to view a full list of research funded to date.
Clinical Trial Updates

As part of the approximately $4 million provided in research funding to date, CRF has supported crucial research that led us to where we are today with gene therapy.

In Fall 2019, the final patients in Biogen’s Phase III STAR gene therapy clinical trial (formerly operated by Nightstar Therapeutics) were treated. These patients, like all those before them, will be followed for one year. At that point, the data will be compiled and brought before the FDA for review and potential approval in 2021. Biogen is also continuing the GEMINI Phase 2 study to determine the safety of bilateral sequential gene therapy for choroideremia.

Spark Therapeutics continues to follow and collect data from their Phase I/II Gene Therapy Clinical Trial participants.

4D Molecular Therapeutics concluded their Natural History Study in early 2019, and developed a novel viral vector for their gene therapy for Phase I Clinical Trials which began in 2020.
International Advocacy Efforts

During 2020, we participated in person and virtually to represent the choroideremia patient voice at numerous events:

Legislative
- US Congress
- Rare Disease Week on Capitol Hill
- Rare Disease Legislative Associates
- Haystack Project – conducting efforts to promote insurance coverage for gene therapy treatments

Regulatory
- Food and Drug Administration
- Center for Biologics Education and Research
- Center for Drug Evaluation and Research
- National Institutes of Health
- National Eye Institute
- National Center for Advancing Translational Studies
Industry Advocacy
- American Society of Gene and Cell Therapy
- International Society of Gene and Cell Therapy
- UK Eye Genetics Group
- US Ophthalmic Genetics Study Club
- International Society of Genetic Eye Diseases and Retinoblastoma

Rare Disease Advocacy
- Global Genes
- Everylife Foundation for Rare Diseases
- National Organization for Rare Disorders
- World Orphan Drug Congress

Inherited Retinal Disease Advocacy
- France Choroideremie
- Zizoz
- Fight for Sight/Tommy Salisbury Fund UK
- Pro-Retina Germany
- CRF Canada
- Retina International
- Foundation Fighting Blindness Genetic Testing

Special Initiatives Advocacy
- Consolidation of CHM Natural History Data: NORD/FDA's Rare Disease Cures Accelerator-Data and Analytics Platform
Programs

We now serve over 12,600 patients, family members, donors, and medical professionals from 68 countries.

In addition to continuing to offer phone and email support for CHMers and their family members, we significantly expanded our digital footprint by conducting:

- “Meet A CHM Family Member” video interviews
- Launching a new home for CHM online support: MyCHM.net
- Developing a new Membership framework to create member engagement
- Hosting 40+ online events since April to create member engagement
  » Webinars
  » Informal Social Chats
  » Support Groups
  » Pre-recorded informational videos
  » Registrants from US, India, Ireland, United Kingdom, Germany, Netherlands, Mexico, South Africa, Canada, Czech Republic, Turkey and more
  » Over 110+ new CHMers and family have registered
- All webinars recorded and posted on our Facebook page
- Over 15,000 views to date of 80+ videos on our YouTube channel
Other Accomplishments

- Received Highest Platinum Rating from charity watchdog group Guidestar
- Great Non-Profits “Top Rated” Charity
- 100 of 100 score from Charity Navigator – “Give with Confidence”
- CRF recorded its first ever video Annual Report. Click here to view the “State of the CRF” webinar on YouTube.
Fundraising

2020 Calendar Year Giving

People Served - 2020
For a long time, Dad was told he had a retinal degenerative disease called retinitis pigmentosa. However, in the 1980’s he learned he had choroideremia (CHM). Based on our family tree, I knew from a young age that I was a “carrier” of the disorder causing my dad to go blind. I knew that I had a 50/50 chance of passing the affected CHM X chromosome to my future children.

In January 2009, our beautiful son was born! We took him to see ophthalmologists starting at a young age so that his retinas could be evaluated. When Sullivan was 4 years old, his ophthalmologist told us that his retinas were showing signs of CHM. At first, I was devastated and sad. I grappled with feelings of guilt in the face of the diagnosis.

However, with the help of the CRF, I learned much more about CHM and the various research trials being conducted, discovered a supportive community, and found rays of hope. I am now dedicated to helping the CRF raise funds to aggressively continue the pursuit of a cure.
From the first conference that I attended in Denver in 2014, the CRF has been a welcoming community. Its taught me more about CHM from the information on the website, conferences, and online activities. I learn about all the research CRF supports and the exciting clinical trials happening around the world. I am in awe of the progress made by scientists and believe these people are a gift from God. What has probably made the most difference in my life is meeting fellow CHMers. It’s kind of hard to put into words what it means to be able to talk with people – after so many years – who know first-hand what it’s like to live with CHM. Blessed? Grateful? Relieved? Yes! Blessed to have made so many friends. Grateful for the researchers who choose this particular disease to find a cure for. And relieved by the belief that my children and grandchildren will never go blind.
Testimonials

Rob Driscoll

CRF has given me so much as a CHMer. The CRF community is something I am forever grateful for.

The CRF has given me so much as a CHMer. First and foremost, the CRF community is something I am forever grateful for. Through the biannual conference, I have found my extended family. While we may have only met a few times, I feel so connected with them. Second, I was selected to be part of a phase 2 trial with Spark Therapeutics. Without the work that the CRF has done, this opportunity would not have been possible. The fundraising efforts, awareness spread and persistence of the CRF to push researchers closer to a cure is amazing.

I am very optimistic for the future in gene therapy and choroideremia. The CHM community has found themselves in an extremely lucky and favorable position in terms of research. As the science continues to improve, we as CHMers already have our foot in the door and are striding alongside the researchers due to the trials across the globe involving CHMers.
Testimonials

Sam Looney

My life forever changed at five years old when I learned the inevitable truth that I had CHM. I say ‘inevitable’ because it’s been a big part of my family for generations – my grandfather had CHM and my mom and sister are carriers. I was prepared to chart this uncertain course in life with the knowledge that my vision would worsen and there would be no hope for treatment, let alone a cure.

The CRF, however, changed everything for scientific advancements, the CHMer community and me. Today, I’m in a gene replacement clinical trial that I 100% believe is due to the vision, tenacity and constant support of the CRF. Twenty years ago, a few CHMers said the current research landscape wasn’t good enough, so this small but mighty group took action. The CRF has funded approximately $4 million in the pursuit of treatment and eventually, a cure. It has also given me a wonderful network of CHMers to lean-on and learn from; they’re some of the toughest and most resilient people on earth.

I learned at a very early age that you need to adapt to adversity, never give up and find a way forward. Being a CHMer has taught me these lessons, and the CRF has shown me that anything is possible.
Board of Directors

Neal Bench
President
Chapel Hill
North Carolina

Tara Cassidy-Driscoll
Treasurer
Swampscott
Massachusetts

John Trott
1st Vice President
Westfield
New Jersey

Brian Mayer
Secretary
Brookfield
Illinois

Michael Mullen
2nd Vice President
Carmel
Indiana

Officers At Large

Chris Moen, MD
Wilmington
Delaware

Stephanie Sims, MD
Jacksonville
Florida

John Oster
Rochester
New York
Directors

Bob Hillier
Ontario
Canada

Angela Ricketts
St. Louis
Missouri

Michael Langsfeld
Friedberg/Hessen
Germany

John-Ross Rizzo, MD
New York
New York

Jason McKinney
Gilmer
Texas

Craig Rowley
Jay
Maine

Dan Peterson
Trimont
Minnesota

Jon Salois
Worcester
Massachusetts

Tracey Pretorius
Kirkland
Washington

Kayla Schiller
Klaflin
Kansas
Scientific Advisory Boards

Ian MacDonald, MD, Chair
Professor, Department of Medical Genetics
University of Alberta Edmonton, Alberta, Canada

Tomas Aleman, MD
Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania, Perelman School of Medicine
University of Pennsylvania Philadelphia, Pennsylvania

Kapil Bharti, PhD
Senior Investigator, Ocular and Stem Cell Translational Research Unit, National Institutes of Health, Intramural Research Program
Bethesda, Massachusetts

Sanford Boye, MS
Associate Scientist, Department of Ophthalmology, Shannon E. Boye Laboratory, University of Florida Health
Gainesville, Florida

Shannon Boye, PhD
Associate Professor, Department of Ophthalmology, Shannon E. Boye Laboratory, University of Florida Health
Gainesville, Florida
Frans Cremers, PhD
Professor, Ophthalmogenetics, Department of Human Genetics and Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center
Nijmegen, Netherlands

Jacque Duncan, MD
Professor in Ophthalmology, University of California San Francisco
San Francisco, California

Rachel Huckfeldt, MD, PhD
Associate Surgeon and Director, Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear; Assistant Professor of Ophthalmology, Harvard Medical School Boston, Massachusetts

Alex Iannaccone, MD, MS, FARVO
Director, Center for Retinal Degenerations and Ophthalmic Genetic Diseases, and Professor, Ophthalmology, Duke University Department of Ophthalmology
Durham, North Carolina

Mark Pennesi, MD, PhD
Assistant Professor in Ophthalmic Genetics, Oregon Health and Science University (OHSU) Casey Eye Institute
Portland, Oregon

Stephen Tsang, MD, PhD
Professor of Ophthalmology and Professor of Pathology and Cell Biology, Columbia University Department of Pathology and Cell Biology
New York, New York
Ajoy Vincent, MBBS, MS
Staff Ophthalmologist, Ophthalmology and Vision Sciences; Medical Director, Visual Electrophysiology Unit; Associate Scientist Genetics and Genome Biology Research Institute, The Hospital for Sick Children
Toronto, Ontario, Canada

Michael Young, PhD, FARVO
Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute; Director, Minda de Gunzburg Center for Retinal Regeneration, Harvard Medical School; Associate Scientist, Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, Massachusetts

Chris Moen, MD
Chief Medical Officer, Choroideremia Research Foundation
Medical Director, NaviHealth
Wilmington, Delaware

Jess Thompson, MD, MS
Chair, Research Committee, Choroideremia Research Foundation
Yavapai Cardiac Surgery
Prescott, Arizona

Staff

Beth Foss
Director of Operations

Eric Hartman
Director of Advocacy

Cory MacDonald
Engagement Director

Kathi Wagner
Executive Director
## Financial Summary

<table>
<thead>
<tr>
<th>Fiscal Year Financials</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations</td>
<td>$538,010</td>
<td>$409,797</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$16,228</td>
<td>$48,562</td>
</tr>
<tr>
<td>Other Income</td>
<td>0</td>
<td>$1,195</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$554,238</td>
<td>$459,554</td>
</tr>
</tbody>
</table>

| **Expenses**           |         |         |
| Program                | $162,909| $111,050|
| Research               | $363,991| $179,775|
| Fundraising            | $60,937 | $60,572 |
| Management             | $53,092 | $47,597 |
| **Total**              | $640,929| $398,994|

| Change in Net Assets   | -$86,691| $60,560 |
| Net Assets, beginning of year | $894,174| $833,614|
| Net Assets, end of year  | $807,483| $894,174|

(July 1 - June 30)
Donors

$10,000+
Biogen
Daniel and Sharyl Boren
Mr. Jason Folie
Genentech
Hugh and Nancy Hutchison
Ms. Mary Porter
Spark Therapeutics, Inc.
Auburn Theta Chi Fraternity, Chi Chapter
Tom Pettit Estate

$5,000-9,999
Allergan Foundation
Anonymous
Ms. Lana Boushee
Ed Lucas Foundation
Ms. Michelle Holbrook
Home Leasing LLC
Kevin and Dawn McCarthy
John and Loron Oster
Joe and Joanne Salois
Ms. Cassey Smith
Mr. Christopher Stern
Mr. Jeff Warner

$2,500-4,999
Atlas Distributing, Inc.
Neal and Jeanette Bench
Jeff and Julie Benelli
Glyn and Betsy Boone
Mr. Dennis Braunshausen
Cannon Heyman & Weiss, LLP
DGA Builders Inc
Edwards Lifesciences Foundation
Glasow Simmons Architecture, LLP
Mr. Charles Gleason, III and Dr. Maryanne Driscoll
Richard and Constance K. Guerin
Cory and Karen MacDonald
Mr. Ken Ogden
John and Sandy Polkowski
Marty and Marilyn Reiss
Salmin, Celona, Wehrle & Flaherty, LLP
Sutton Real Estate Company LLC
Tim and Janet Whalen
ZS Associates

$1,000-2,499
Amazon Smile
Anonymous
William and Barbara Barr
Mr. William Bauer
Roland and Margrit Bechade
Mr. Chris Bellon
Bruce and Jane Bench
Ms. Stephanie Benson
Stephen and Carol Brennan
Craig and Ellen Brown
Ms. Gloria Calhoun
Mrs. Marilyn Cassidy
Tom Driscoll and Tara Cassidy-Driscoll
CB Emmanuel Realty LLC
Charles A. Gaetano Construction Company
Cornell Dubilier Electronics, Inc.
Mr. Daniel Crossland
Mr. Mark DeFranco
William Seymour and Rosemary Driscoll
Edgemere Development, Inc.
Eyecare Partners LLC
John and Barbara Fenner
Mr. Andrew Foley
Bob and Beth Foss
Frank E. Neal & Co., Inc
Ms. Ann Gillespie
Go Green Clean LLC
Mr. Joseph Halder
Sean and Sharalyn Hoffman
Richard and Pam Holley
IN/EX Architecture, P.C.
ISAAC Heating and Air Conditioning
Mr. Paul Janczyk
Mr. Peter Jarrett
Tim and Susan Kazmierczak
Marathon Engineering
Ms. Susan Marshall
Meidinger Family Charitable Fund
Merck Foundation
Michael and Frances Peters Family Fund
Michael and Kimberly Monahan
Mr. Michael Mullen
Nahant Lions Club
Bernard and Shari Nutter
Lin and Laura Ogg
Charles and Patricia Oster
Bob and Paige Pettipaw
Plan Architectural Studio, P.C.
QPK Design, LLP
Matt and Angela Ricketts
Mr. Ross Rizzo
Mr. Yamil Rosete-Rodriguez
Earl and Ellen Russell
Edward and Marion Scott
David Stateman and Sondra G. Hoffman
Ms. Suzanne Sullivan
Dr. Jess Thompson and Mrs. Sarah Thompson
Vrishali Thorat
John and Dominique Trott
Veach Family Fund

**$500-999**
Advanced Sight Center, Inc.
Mr. Joel Anderson
Bausch and Lomb/Bausch Foundation
Mr. Brandon Becker
Mr. Jeffrey Bench
Mr. Shane Boone
Mr. John A. Brownell, Sr.
Carbon-Stillwater Tavern
Assoc.
Mr. James W. Coghlin
Jack and Jeani Cunningham
PJ and Dawn Dearden
Ms. Martha P. Dolben
Dunn-French Foundation
Ms. Ruth Edwards
Eric Gleason Construction, LLC
Charlie and Jane Ezzell
Mr. Tim Flaherty
Mr. James P. Folie
Folie Roofing
Mr. Allen Frederick
Joseph and Brenda Garrison
Google
Google Matching Gifts Program
Ms. Tina Green
Lawrence and Wynette Hall
Robert and Bettye Halperin
Ms. Alicia Harris
Dr. Michael Harvey
Ms. Kimberly Heitert
Mr. Benjamin Holthus
Ms. Janet Jakobe-Gray
Ms. Frances Jenkins
Mr. Jim Joaquin
Mr. Graham Johnson
Kerry Jones
Mr. John Kane
Ms. Helen Kelly
Mr. Simon Keymer
John and Janet Laudenbach
Mr. Adam Leach
Lions Club Of Grayslake Foundation
William Wilson and Jennifer Maude
Brian Mayer
Ms. Gretchen McClain
Sean and Jodi McLaughlin
Ms. Victorine Meriman
Microsoft Gift Match
Mr. Thomas Miller
Christopher and Alisa Moen
Ms. Ann Nally
Ms. Jody Nelson
NetApp, Inc.
Mr. Jay Nicolin
Mr. Greg Nowak
Kevin and Maureen O’Beirne
Mr. John R. O’Leary
Mr. Joseph Oster
Ms. Sarah Pennington
Mr. Dan Peterson
Mr. Stephen Pettipaw
Mr. Scott Petts
Ms. Patricia Priest
Mrs. Diana Pully
Ms. Janee Rasmussen
Donald and Louise Richards
Mr. Jack Ricketts
Mr. Robert Ritchie
Mr. Daniel Robbins
Ira and Erica Robbins
Ms. Debra Ropp
Mr. Jonathan Salois
Schumacher Electric, Inc.
Mr. Dale Shumway
Skorupski Family Funeral Home and Cremation Services
Mr. Gregory L. Skuta
Mr. Andrew Somers
Southwest Airlines
Mr. James Stanford
Streamline Communication LLC
Mr. Jeffrey Thom
John Tiedemann, Jr. and Stephanie Tiedemann
Mr. Chris R. Ullrich
Mr. Peter Vars
Mr. Kevin Walker  
Mr. Dewayne Wesley  
Ms. Debbie Williams

$250-$499  
Agawam Dental Care P.C  
Alexander Lumber  
Mr. John Anderson  
Ms. Sarah Andres  
Anonymous  
Mr. Stephen Appelbaum  
Ms. Sylvia Bediamol  
Mr. Tyler Bench  
Mr. Scott Besser  
Ms. Nicole Blondin  
Josephine McCarron  
Mr. Ross Bremner  
Ms. Elizabeth Brennan  
Ms. Lyric Butler  
Mr. Matthew Buyske  
Ms. Danielle Campbell  
Ms. Susan Castle  
Beron and Lorraine Chamberlin  
Chubb Charitable Foundation  
Clarks Grove - Waseca Veterinary Clinic, L.L.P  
Ms. Maria Craft  
Cummings Floor Covering  
Deml Ford Lincoln Mecury  
Mark and Susan DeVoe  
Neil and Barbara DiTrani  
ECHO - Northrop Grumman  
Ms. Karen Finklang  
First National Bank - Waseca  
Mr. Jonathan Fischbach  
Mr. Maxx Frost  
Mr. Jeremy Gelbwaks  
Greater Horizons  
Joe and Diane Gullo  
Ms. Michelle Hans  
Mr. Stan Hardaway  
Mr. Oliver Harel  
Ms. Sarah Hart  
Mr. H. Eric Hartman  
Ms. Holly Haslam  
Ms. Erin Hausmann  
Mr. Patrick Heafner  
Ms. Pamela Hemminger  
Ms. Linda Hirsch  
Mr. Kurt Hirsch  
Mr. John Hirshberger  
Mr. Ryan Hoffman  
Ms. Darcy Hunter  
Mr. Tom Jacobson  
Ms. Holly Kalish  
Michael and Gail Kane  
Ms. Katherine Kelting  
Ms. Patricia Kjolhede  
Ms. Krista Kramer  
Mr. Josh Kunz  
Mr. Scott T. Lang  
Mr. Nick LaPier, CPA  
Mr. Jacob Lee  
Robert L. and Linda Lund  
Mr. Matt Luzecky  
Ms. Tracy Maag  
Marathon Petroleum Company  
Mr. Patrick McGinnis  
Jason and Tara McKinney  
David and Maria Moen  
Nordson  
Mr. Thomas Oldenburg  
Mr. Matt Oster  
Ms. Ruth Owens  
PayPal Giving Fund  
Ms. Joyce Peterson  
Mr. Matthew D. Pfarr  
Ms. Mikelle Phillips  
Mr. John Powell  
Rollie and Sandra Purvis  
Steven and Elizabeth Reiling
With a planned gift to the Choroideremia Research Foundation, you can combine your desire to give to charity with your overall financial, tax, and estate planning goals.

Planned giving gives you a special connection with CRF. You will help those affected by choroideremia—for now and for years to come.

For more information, please contact Kathi Wagner, Executive Director, at 800-210-0233 x 5 or kathiwagner@curechm.org.
Mr. Mark Brown
Ms. Susan Bryan
Ms. Sharon Bushnell
Ms. Julie Cameron
Keith and Barb Cameron
Cardi’s Furniture & Mattress
Ms. Renee P. Carey
Ms. Brandy Carman
Ms. Deborah Carney
Chris Carter and Karen Ranikin
Ms. Sandy Carver
Michael and Patricia Cavanagh
Mr. Martin Caylor
Mr. Bruce P. Chamberlin
Mr. Gerald Chapski
Carey Chenoweth
Chevron Humankind Matching Gift Program
Jon and Patricia Christiansen
Jay and Debbie Clark
Mr. Stephen Cline
Richard and Carolyn Cofer
Ms. Colleen Comeau
Mr. J. Matthew Conaty
Ms. LouAnne Connell
Mr. Brad Connors
Connors Pluming & Heating, Inc.
Ellie Corbett Hannum
Mr. Bret Corrigan
Paul and Mary Costantino
Mr. Michael Cox
Ms. Julia Cox
Jeffrey Cox and Lisa Mitchell
Richard and Barbara Craig
Mr. Spencer Crawford
Mr. Clay Crownover
Mr. Edward Crumley
Mitch and Nancy Cubrich
Mr. Dan Cunningham
Ms. Cynthia Currey
Mr. Daniel Czubak
Ms. Elizabeth Daaleman
Mr. Jerry Darko
Dependable Hardwood Floors
Ms. Diane Dillard
Ms. Kristin Dobbek
Ms. Carolyn A. Donnelly
Ms. Barbara Driscoll
Mr. Robert Drouin
Ms. Evelyn Dueck
Mr. Richard Dumont
Ms. Anne Duncan
Ms. Tammy Duzan
Mr. Tristran Eddy
Ms. Maryann Ekerberg
Mr. John Elchinger
Ms. Raina Enand
Mr. Roman Erenshteyn
Ms. Zhanna Erenshteyn
Andrew and Ceri Erskine
Ms. Carolyn Falletta
Ms. Veronica Ferro
Fette’s Package Store
Roy and Pamela Finkelman
Mrs. Faith Ford
Ford Motor Company Fund
Fountain Plating Company, Inc.
Mr. Christian Fox
Ben and Wynne Wilson Freeman
Shawn Fresolone
Ms. Lynne Fuente
Ms. Jennifer Galvagna
Ms. Barbara B. Garcia
Mr. Mark Gasaway
Mr. Andrew Genetti
Mr. Richard Glatzmaier
Mr. James Glatzmaier
Ms. Sharon Gnann
Mr. Jacob Goergen
Ms. Kim Gohl
Ms. Catherine Gohl
Mr. Kenneth Goldman
Mr. Peter Gorgone
Ms. Shir Gottlib
Kelly Gower
Mr. Henry Grabowski
Ms. Sharon Grammer
Ms. Christine Griffin
Mr. Jeffrey Grobe
Ms. Dawn Groh
The Groom Family
Mr. Brandon Gross
Mr. Erwin Gutsell
Mr. Jeffrey Guy
Ms. Susan Cook Guzman
Add and Janice Hagan
Ms. Lisa Hall
Ms. Jean Hall
Ms. Jean Hamilton
Mr. Blake Hammer
Marty Hancock
Ms. Marilyn W. Hartman
Mr. Brandon Hasenstab
Ms. Annecia Hasler
Ms. Joyce Hawkins
Ms. Susan Hayward
Ms. Kim Hennigar
Ms. Kenneth Herschfield
Mr. Kurt Heyman
Mr. Ken Hibbard
Robert and Martha Hillier
Mr. Ashok Hingorany
John and Patty Hirshberger
Ms. Pamela Hirth
Mr. Thomas Holbrook
Kaz L. and Shannon Holley
Saralinda Hooker
Ms. Marcia Hopple
Mr. Kyle Hotaling
Mr. Gregory Huguely
Ms. Linda Rosland
Mr. George Rossi
Ms. Andrea Roueche
Ms. Amy M. Ryan
Mr. Jason Sackett
Ms. Suzanne E. Samson
Tamara and Rob Sanders and Noti
Ms. Petra Schaefer
Ms. Susan Schiffhauer
Ms. Kayla Schiller
Mr. Parker Schlink
David and Patricia Schmidt
Jim and Barbara Schroeder
Ms. Mary Schulte
Ms. Carol Schulte
Mr. Matthew Schultz
Schwab Charitable
Mr. Bob Scott
Mr. Michael Scott
Mr. Vincenzo Andrea Selvaggi
Mr. Hubert E. Seymour, III
Shivani Shah
Ms. Ellen Shain
Mr. Mike Sharkey
Ms. Martha Sharpe
Mr. Steven Shaughnessy
Gustavo and Sharie Sierra
Mr. Gary Silverman
Dr. Stephanie Sims
Ms. Denise Sims
Ms. Julie Smith
Mr. Ken Snell
Mr. John Spinale
Ms. Susan Sprague
Robert and Jennifer Staley
Jessup Standifer
Devin Stearns
Ms. Patricia Stelz
Ms. Alyssa Straight
Mr. Joseph Stumpf
Ms. Paulette Talbot
Ms. Teresa Tatton
Ms. Margo Taylor
Mr. Michael F. Teodori
Ms. Michelle Tessier
Ms. Karen Tessier
Ms. Lori Winston Thaman
Vicky Thomas and Anthony Morelli
Calvin and Carol Thomas
Mr. Rodney Thompson
Timms Trucking
Ms. Jocelyn Tinsley
Ms. Amelia Titus
Dean and Trena Trowhill
Alan and Andrea Trowhill
Ms. Martha W. Turvey
Two Blind Brothers
Ms. Carol Updike
Mr. Seth Vanderswaagh
Mr. Peter Vaream
Mr. Stephen Varughese
Dr. Anthony Vetere and Daniele Vetere
Ms. Connie Vignes
Ms. Carolyn Vitale
Joe and Kathi Wagner
Ms. Sibyl Wagner
Mr. Don Walker
Ms. Lori Walsh
Ms. Katie Walstrom
Ms. Karen Watson
Mr. Jeff Weaver
Ms. Denise Weaver
Mr. Thomas Weckesser
Ms. Cathy Wegener
Ms. Ginger Weiss
Mr. Chuck Whitbeck
Ms. Kaylah White
Mr. Joe White
Ms. Diana Widicus-Davis
Ms. Sheryl Wilder
Ms. Mary Wilson
Ms. Marie Wilson
Ms. Jessica Wilson
Mr. William Wilson
WMAS Radio
Peter and Catherine Woll
Marin Worornets
Mr. John Wren
Mr. Rod Wright
Mr. Michael Zawacki
Xilong Zhao
Ms. Ann Zurn

Every effort has been made to recognize each donor correctly. We apologize for any omissions or errors. If we need to make corrections to your listing, please call us at 800-210-0233, ext. 1 or email us at info@curechm.org.